Updated Phase 2b data show fewer major cardiac events in HLHS
Longeveron released updated results from ELPIS II, its Phase 2b randomized trial of Laromestrocel given as an adjunct during Stage II palliative surgery in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary efficacy endpoint of change in right ventricular ejection fr
<p>Longeveron released updated results from ELPIS II, its Phase 2b randomized trial of Laromestrocel given as an adjunct during Stage II palliative surgery in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary efficacy endpoint of change in right ventricular ejection fr</p>